Millipore Corporation has completed the acquisition of MicroSafe, B.V., for approximately $9.3M. MicroSafe is a contract laboratory that develops assays and provides a range of testing services to help leading European biotech and pharmaceutical customers monitor for quality and compliance in the drug manufacturing process. The company employs thirty professionals and is based in Leiden, The Netherlands.
Martin D. Madaus, Millipore’s Chairman, CEO and President noted: “We are very pleased that MicroSafe is becoming part of Millipore. They have a loyal client base and the expertise that will help us expand the scope of service we offer to our biotech and pharmaceutical customers, particularly in the area of virus and mycoplasma testing. Their application knowledge will also help us accelerate development of products and systems for rapid process monitoring.”
Fathia Methnani, Managing Director of MicroSafe, B.V., commented: “With Millipore’s market presence in Europe and scientists and applications specialists in the field we will be able to bring our services to more clients and we’ll be able to expand those service offerings.” Ms. Methnani will continue to direct MicroSafe operations.
MicroSafe, with annual revenues of $4 million, has received GMP and GLP approvals and is currently expanding its capabilities to meet growing customer needs.